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ABSTRACT  
 
Endovascular abdominal aortic aneurysm repair (EVAR) was initially developed to treat patients 
with a less invasive method. The first promising results of this new method showed shorter hospital 
stay and less morbidity than open repair. Later in non-randomised studies the operative mortality 
seemed to be lower compared to open repair, whereas the durability of EVAR and the potential 
need for complicated re-interventions became a major concern. 
 
The aim of this study was to evaluate how EVAR has fulfilled some of the expectations of a less 
invasive method with a better outcome of the patient. 
 
The methods of the study were: 
1. The results of all the 229 EVAR patients treated in Finland between 1996 and 2000 were 
assessed and compared to the results of the large multicenter EUROSTAR registry with 
2464 patients during the same time period. 
2. In a prospective, non-randomised study the effects of surgery in renal function was 
compared in 15 EVAR patients and nine open AAA repair patients.  
3. The treatment results, follow-up data and conversions of all 110 elective EVAR procedures 
performed at the Helsinki University Central Hospital between 1996 and 2004 were 
gathered prospectively and evaluated. 
4. In a prospective, non-randomised study we compared the impact of intra-aneurysmal 
thrombus mass and the effects of surgery, on the interplay between coagulation and 
inflammation in open and endovascular abdominal aortic aneurysm repair. 
 
The results of the study were:  
1. The short-term results of endovascular treatment with a low (0.9%) mortality seem to be as 
good as or even better than those of open elective repair. The mid-term results with mostly 
first-generation endografts are more disappointing because of the detected endoleaks, the 
risk of late rupture, stent graft kinking and numerous graft limb thromboses and the need for 
secondary interventions. 
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2. Temporary renal tubular dysfunction is found both in open and in endovascular AAA repair 
which do not lead to permanent changes in renal function. Endovascular AAA repair does 
not protect renal proximal tubular function.  
 
3. Conversions seem to be less hazardous when performed electively. Elective conversion 
could be an alternative treatment method in complex failing first-generation stent-grafts as it 
may reduce the mortality associated with urgent conversions. 
 
4. Preoperatively both the prothrombotic and the fibrinolytic mechanisms are activated in 
patients with AAA. The activation seems to persist in EVAR patients three months 
postoperatively. The intraluminal thrombus may induce prothrombotic and inflammatory 
interactions, which may counteract the potential benefits gained with endovascular aortic 
aneurysm repair. 
 
In conclusion, EVAR seems to have fulfilled only some of the short-time expectations. Though the 
operative mortality has been reduced, we found no beneficial effects of EVAR in renal function 
tests or in the coagulation or inflammation responses of the patient. On the contrary, the ongoing 
inflammatory process and coagulation activity in the intra-aneurysmal thrombus remaining after 
EVAR may be harmful to the patient. The mid-term results of the durability of EVAR have been 
concerning, with numerous graft-related complications detected and a need for complicated re-
interventions. The lack of long-term results in randomised studies comparing EVAR and open 
repair still question the true benefits of EVAR. 
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INTRODUCTION 
 
Abdominal aortic aneurysm (AAA), a dilatation of the abdominal aorta, is defined as the maximum 
infrarenal aortic diameter being 30 mm or more (McGregor et al. 1975). As the diameter of the 
infrarenal aorta is dependent on age and sex (Grimshaw and Thompson 1997), a size of at least 1.5 
times greater than the expected normal diameter of the infrarenal aorta (Johnston et al. 1991) has 
been suggested as a definition of an aneurysm. 
 
The exact incidence of AAAs is not known. The reported incidence varies with age and gender, 
being highest in elderly males. An incidence of new asymptomatic aneurysms of 350 per 105 
person-years was found by screening twice 4070 men over the age of 50 in the UK (Wilmink et al. 
2001). A 4-year incidence of 2.6 % was found in another similar study of 2622 subjects (Lederle et 
al. 2000b). According to ultrasound screening and autopsy series, the prevalence of AAAs in 
Western countries in the population over 50 years of age is 3 % to 10 % (Chichester Aneurysm 
Screening Group et al. 2001, Lederle et al. 2000a). The reported incidence of ruptured AAAs varies 
between 6 and 21 per 105 person-years (Choksy et al. 1999, Kantonen et al. 1999) and a ruptured 
AAA is six times more common in males than females (Choksy et al.1999). According to a Finnish 
national database (the Statistics Finland), ruptured AAA was the 12th leading cause of death among 
men over 65 years in 2003.  
 
An AAA is usually asymptomatic until it ruptures. The risk of rupture is in proportion to the size of 
the aneurysm. Small (under 50 mm) aneurysms rarely rupture, but the risk exceeds 5-10 % per year 
in aneurysms between 50 to 60 mm to over 10 % per year in even bigger aneurysms (Law et al. 
1994). In order to avoid the high mortality associated with aneurysm ruptures (Kantonen et al. 
1999), elective techniques for aneurysm repair have been developed since the beginning of the 19th 
century: first with ligation, wiring or wrapping of the aneurysm, and later with homograft 
replacement of the aneurysm (Dubost et al. 1952). Most of these early procedures proved to be 
unsuccessful, until the introduction of open resection and replacement of AAA using knitted dacron 
graft more than 50 years ago (Orr and Davies 1974). This approach has been the golden standard for 
AAA treatment (Zarins and Harris 1997) in both elective and ruptured cases. There is a high 
mortality rate associated with AAA ruptures, approximated to be 88 % overall (Bengtsson and 
Bergqvist 1993). The mortality is high even among those patients reaching hospital alive and being 
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operated; only every second of them survive in population-based nationwide studies (Kantonen et 
al. 1999, Korhonen et al. 2004). The corresponding total in-hospital mortality for ruptured 
abdominal aortic aneurysms has been 63%-68 % in Finland (Heikkinen et al. 2002, Kantonen et al. 
1999). According to most of the literature the outcome of ruptured abdominal aortic aneurysm 
(RAAA) has remained unchanged, although contradictory results have been achieved by 
centralisation and organisational measures as shown by Laukontaus et al (unpublished data). The 
operative mortality has remained rather unchanged (Paaske et al. 2005). In elective open aneurysm 
repair, the mortality is substantially lower, approximately 5 % (Kantonen et al. 1997). Still, the 
operative risk is higher among patients with severe co-morbidities (Steyerberg et al. 1995).  
 
A new, endovascular method for aneurysm repair (EVAR) was introduced by Volodos and Parodi 
(Parodi et al. 1991, Volodos' et al. 1988), without the need for open surgery and with high 
expectations of lower morbidity and mortality, especially among patients with co-morbidities (Cao 
et al. 2004) over a decade ago. Enthusiasm and expectations of this new technique were high in the 
middle of the 1990´s. The first EVAR in Finland was performed at the Surgical Hospital in Helsinki 
in November 1996 (Aho et al. 2001). Since the initial experiences by Volodos and Parodi, over 
50,000 AAA patients have been treated endovascularly (van Sambeek et al. 2004) despite the 
investigational nature of the procedure (Collin and Murie 2001, Rutherford 2004). First randomised 
trials comparing EVAR and open aneurysm repair are still underway (EVAR trial participants 
2005a, EVAR trial participants 2005b). 
 
In the present studies the aim is to assess how endovascular aneurysm repair have fulfilled these 
expectations by analysing the early results of EVAR in Finland, the mid-term results in Helsinki 
University Central Hospital, and by comparing the effects of EVAR and open aneurysm repair on 
renal function, coagulation and inflammation. 
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REVIEW OF THE LITERATURE 
 
DEFINITION OF ENDOVASCULAR AORTIC ANEURYSM REPAIR 
 
Endovascular aortic aneurysm repair (EVAR) was first introduced by Volodos in the Ukraine 
(Volodos' et al. 1988) and Parodi in Argentina (Parodi et al. 1991). The idea was to isolate the 
aneurysm from blood circulation by introducing a prosthesis from the femoral artery up into the 
aneurysm and to fix the prosthesis to the normal parts of aorta with stents. By doing this, the 
prosthesis isolates the aneurysm from blood flow and systolic pressure, thus avoiding the risk of 
aneurysm rupture. The procedure is less invasive than open aneurysm repair, as no laparotomy or 
aortic cross-clamping is needed, and it may be performed even under local anesthesia. 
 
After the first reports, a wide enthusiasm to this new technique spread among vascular surgeons and 
radiologists around the world. The initial principal aim of this minimally invasive technique was to 
offer a treatment method, which would prevent an aneurysm rupture, and death in patients with 
multiple illnesses, who probably would not tolerate open repair of the aneurysm (Faries et al. 2003). 
Since the first experiences the new method was widely applied also to patients fit for open surgery 
in order to avoid the drawbacks associated to open surgery (White et al. 1996). 
 
In Finland the feasibility of AAA patients suitable to have endovascular treatment was 
approximated to be 27 % in the very early stage of EVAR experience (Lepantalo et al. 1997). Since 
then thousands of patients have been treated endovascularly worldwide and follow-up data of these 
patients have revealed the limitations of endovascular treatment, and the patient selection criteria 
have become more specific with exclusion criteria mainly involving anatomic restrictions of the 
aneurysm predicting long-term failure of the treatment. Still, in the most enthusiastic centres, a 
majority, up to 75-78 % of patients, are treated endovascularly (Dias et al. 2003, Du Toit et al. 
2005). 
 
Open AAA surgery carries a substantial morbidity and mortality. The negative effects related to 
surgery are consequences of the operative trauma, changes in renal blood flow induced by the aortic 
clamping, blood loss and ischemia-reperfusion injury of the lower part of the body and the 
intestines. These negative effects can cause disturbances in renal function, hemostasis, and 
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activation of the inflammatory system leading to multiple organ dysfunction syndrome (MODS), 
multi-organ failure (MOF), and death. 
 
The expectations of EVAR being safer to the patients are based on the less invasive nature of the 
procedure leading to lesser surgical and physiological stress reaction of the patient, without a need 
to clamp the aorta thus avoiding the negative effects related to ischemia-reperfusion injury, lesser 
blood loss and faster recovery of the patient. These factors are expected to lead to a better outcome 
of the patient (Longo and Eskandari 2004). 
 
THE OUTCOME OF ENDOVASCULAR AORTIC ANEURYSM REPAIR 
 
Overview 
 
After the first experiences of endovascular aneurysm repair, the short-term results regarding 
morbidity and mortality of EVAR were at least as good as in open repair of AAA (Longo and 
Eskandari 2004). After a few years follow-up of home-made or first-generation commercial 
endovascular devices an increasing amount of alarming features were noticed. The durability of 
endovascular repair was questioned as a portion of endografts did not withstand the pulsatile forces 
of blood circulation: the proximal fixation of the endograft moved (migration), some stent-grafts or 
limbs were bent (kinking) or occluded, holes were found in the graft material and fractures in the 
stents. Endotension, a new complication type, specific for endovascular repair, was described. The 
high number of adverse events detected during the follow-up ascertained that a considerable 
number of patients needed secondary maintenance procedures in order to maintain the integrity of 
the stent graft, and all patients had to be followed up regularly with radiographic images (Zarins et 
al. 2004). Still, some aneurysms ruptured despite endovascular treatment (Zarins et al. 2000). These 
worrisome features led to withdrawal of many of the commercial devices and replacement with 
enhanced new models promising better durability (Figure 1). The mid-term results of first-
generation devices were more or less disappointing, but the development of stent-graft materials 
and technology was expected to overcome these problems, at least among the growing number of 
proponents of EVAR. Since then, most of the endovascular devices have been remodeled in order to 
give better long-term results, but still the durability of EVAR is uncertain and many authorities 
share the opinion that EVAR should be used only in patients with a rather short life-expectancy 
(Cronenwett 2005). An even more sceptic opinion claiming that endovascular repair is a failed 
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experiment was published as a leading article in the British Journal of Surgery (Collin and Murie 
2001). Some enthusiasts have, on the contrary, proposed that EVAR should be used in younger 
patients with small aneurysms, which have a long, narrow infrarenal neck and would be easier and 
safer handled with EVAR (Zarins et al. 2005).  
 
 
 
Figure 1. Various stent graft models used at the Helsinki University Central Hospital. Reproduced 
from Aho et al. 2001, with permission. 
 
Mortality and morbidity 
 
In most studies, the mortality of EVAR has been lower than in open repair (Arko et al. 2002a, 
Greenhalgh et al. 2004). As for open repair, the perioperative mortality rate is higher in increased-
risk patients (6.5 % vs 1.8 %) (Chaikof et al. 2002a). EVAR has also reduced the early and late 
morbidity compared with open repair (Arko et al. 2002b) but there are also reports of EVAR being 
associated with a higher complication rate than open surgery (Liewald et al. 2001a). The 
comparisons between EVAR and open repair are somewhat skewed as until now all the reports are 
non-randomised, and there is selection bias, as those patients with an aneurysm not suitable for 
endovascular repair tend to have larger aneurysms with a short infrarenal neck. These patients are 
usually also older and sicker than those treated with EVAR. On the other hand, relatively low in-
 16 
  
hospital mortality rates have been achieved using EVAR in patients with co-morbidities, and most 
authors have proposed that EVAR would be especially beneficial for high-risk patients (Biebl et al. 
2005, Marin et al. 2003, Rutherford 2004, Tonnessen et al. 2004, Verzini et al. 2002). 
 
The first mid-term report of a randomised study comparing open and endovascular repair have 
recently been published in The Lancet (EVAR trial participants 2005a). According to EVAR 1 trial, 
there was no difference in the all-cause mortality between endovascular and open repair in patients 
fit for open repair four years after randomisation. However, the lower 30-day mortality (1.7 % vs 
4.7%) achieved in endovascular repair previously reported in the same trial (Greenhalgh et al. 2004) 
still persisted as a lower aneurysm-related mortality (4 % vs 7 %). EVAR 2 trial compared best 
medical treatment and EVAR in those patients not fit for open repair, with no difference in the all-
cause mortality between the groups four years after randomisation (EVAR trial participants 2005b). 
 
Adverse events 
 
EVAR leads to more complications and reinterventions than open repair (EVAR trial participants 
2005a) and is therefore not as durable as open repair (Dattilo et al. 2002). In the EVAR 1 trial at 
four years after randomisation, there were postoperative complications in 41 % of patients in the 
endovascular group compared to 9 % in the open repair group. 
 
Endoleak 
 
Endoleak is defined as the persistence of blood flow outside the lumen of the endograft but within 
the aneurysmal sac (White et al. 1997) (Figure 2). Thus, an endoleak means an incomplete 
exclusion of the aneurysm from the circulation, and may result from an incomplete seal between the 
endograft and the blood vessel, or between components of a modular prosthesis, defects of the stent 
graft fabric, or retrograde blood flow from patent arterial side branches (Table 1) (Chaikof et al. 
2002b). An endoleak may perfuse and pressurize the aneurysm sac, lead to aneurysm expansion, 
and may also lead to rupture of the aneurysm and death of the patient (Zarins et al. 2000). The 
natural history and consequences of endoleaks are not well understood. The majority of primary 
endoleaks are known to seal spontaneously, without any negative effects on the patient outcome 
(Makaroun et al. 1999). Type I and III endoleaks are considered most concerning as they perfuse 
the aneurysm sac directly in an antegrade manner, whereas a type II endoleak is less concerning 
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with a retrograde perfusion of the sac. This is also confirmed in an analysis of the EUROSTAR 
database, which showed that type I and III endoleaks correlated with an increased risk of aneurysm 
rupture or conversion, whereas type II endoleaks did not. Furthermore, in a later EUROSTAR 
analysis, type II endoleaks were considered alarming as they were associated with an enlargement 
of the aneurysm, and reinterventions (van Marrewijk et al. 2004). According to the EUROSTAR 
results, type I and III endoleaks should always be treated, but type II endoleaks only if the aneurysm 
is expanding (van Marrewijk et al. 2002). Yet some authors have proposed early interventional 
treatment of type II endoleaks (Liewald et al. 2001b) or delayed intervention after six months if still 
present (Terramani et al. 2003). 
 
Table 1. Classification of endoleaks. 
Type Cause of endoleak 
I Inadequate seal at a) proximal or b) distal end of endograft or c) at iliac occluder plug. 
II Retrograde flow from patent visceral vessel (inferior mesenteric artery, lumbar, internal iliac 
artery). 
III Flow from a) module disconnection or b) fabric disruption. 
IV Flow through porosity of fabric. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Various origins of an endoleak. Black arrows: type I 
endoleak from proximal and distal attachment sites and type III 
endoleak from module disconnection. White arrow: type II 
endoleak from a patent lumbar artery. Reproduced from Aho et 
al. 2001, with permission. 
 18 
  
 
Endotension 
 
An AAA may continue to enlarge and eventually rupture despite endovascular treatment. This 
enlargement which is not associated with a detectable endoleak is classified as endotension 
(Chaikof et al. 2002b, White et al. 1999), or by some authors type V endoleak (Gilling-Smith et al. 
1999). The pressurization of the aneurysm sac without endoleak is explained by several different 
mechanisms, including blood flow below the sensitivity limits for detection, pressure transmission 
through thrombus or through endograft fabric (Chaikof et al. 2002b). As endotension cannot be 
treated endovascularly, an open conversion is considered mandatory to end continuing aneurysmal 
growth and risk for rupture (Hiatt and Rubin 2004, van Sambeek et al. 2004). A non-operative 
approach for follow-up in clinically asymptomatic patients has also been proposed (Mennander et 
al. 2005). Furthermore it has been supposed, that endotension could also be treated by laparoscopic 
fenestration of the aneurysm sac, but there is no evidence to support any treatment option (van 
Sambeek et al. 2004). 
 
Migration 
 
Migration is defined as a movement of an endograft of more than 10 mm relative to anatomic 
landmarks or any movement of an endograft leading to symptoms or requiring therapy (Chaikof et 
al. 2002b). The incidence of migration varies between 0 and 45 %. It may, however, be 
underreported, as the insidence is dependent on the follow-up regimen of the patients, and the 
endograft device used (Tonnessen et al. 2004). Migration may lead to type I endoleak and is 
considered a major risk for aneurysm rupture (Buth et al. 2002). Migration may also lead to kinking 
and graft limb occlusion. Proximal migration is generally treated with an extension cuff, or when 
this is not possible, with conversion to open repair (Tonnessen et al. 2004). 
 
Kinking and graft limb thromboses 
 
Kinking of an endograft may lead to a graft limb stenosis and a compromised lower limb blood 
supply, or to complete thrombosis of the endograft limb. A thrombosis of an endograft limb is more 
common in first-generation stent grafts without external support (stent) along the whole length of 
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the graft (Fairman et al. 2002). Furthermore, the number of limb occlusions reported is dependent 
on the stent graft type and the patient selection criteria used, and is reported as high as 7.3 % in a 
report of several stent graft types (Conner et al. 2002). Thrombosed endograft limbs may be treated 
with thromboembolectomy or thrombolysis and stenting of the stenosis, or with a cross-over 
femoro-femoral bypass (Woody and Makaroun 2004). 
 
Material fatigue and structural failures 
 
Material fatigue was especially a problem in home-made and first-generation endografts. When 
endografts were removed during conversion or at an autopsy, there were found holes in the 
endograft fabric and breaks in the integrity of metallic graft components (Chuter 2003). In order to 
detect metallic fractures, the manufacturer of Vanguard, one of the most frequently used first-
generation endograft, advised physicians to follow patients with regular plain radiographs. Yet in up 
to 20 % of Vanguard devices there were found suture breaks and consequently loosening or 
dislocation of structural components (Rutherford 2004).  Eventually the Vanguard graft was 
withdrawn from the market, like many others. Structural failures have been observed with most 
endografts, but attempts to solve the problem have been made by device modifications. These 
newer devices are expected to overcome the problems of endograft durability, but long-term follow-
up results are still awaited to establish this. The lack of proven durability has made the need for 
indefinite surveillance mandatory (Rutherford 2004). The problems of device integrity may be 
endovascularly treated with extension cuffs or additional main body or limb parts deployed inside 
the compromised endograft, or when this is not possible, with conversion to open procedure. 
 
Aneurysm ruptures following EVAR 
 
Late ruptures have been the most worrisome complication observed after endovascular treatment, 
and occurred in the EUROSTAR database in 35/4291 (0.8 %) patients. The cumulative rate of 
ruptures in the first year was 0.3% and 1.0% annually thereafter (Buth et al. 2002, Enzler et al. 
2002). Significant risk factors for late ruptures were endoleaks, graft migration, kinking and 
enlarging aneurysms (Buth et al. 2002, Enzler et al. 2002). The mortality related to such ruptures is 
similar to patients without prior endovascular treatment (Bernhard et al. 2002). 
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Follow-up regimen and secondary interventions 
 
Due to the late problems detected in endovascular repair, life-long surveillance of the patients is 
mandatory (Biebl et al. 2005, Stavropoulos and Baum 2004). In most centers, surveillance is 
accomplished with annual computed tomography angiography (CTA) (Stavropoulos and Baum 
2004). As the use of CTA exposes the patient with ionising radiation and nephrotoxic contrast 
media, lately a follow-up regimen using partially ultrasound controls and abdominal x-ray instead 
of CTA have been proposed (Arko et al. 2004, Verhoeven et al. 2004). 
  
Secondary interventions are needed in some 15 % of endovascularly treated patients to overcome 
the late problems related to endovascular repair (Arko et al. 2002a, Biebl et al. 2005, May et al. 
2000). The number of secondary procedures tends to increase with the length of the follow-up, as 
observed in the prospective voluntary registry of endovascular treatment of aneurysms (RETA) with 
the cumulative freedom from secondary procedures of 62 % at five years of follow-up (Thomas et 
al. 2005). The improvements in endograft design have been shown to reduce the need for secondary 
interventions and conversions (Resch et al. 2002, Torella 2004). Most of the secondary 
interventions are performed due to different types of endoleaks (May et al. 2000), but secondary 
procedures may also be needed after open AAA repair. Indeed, the study by Arko and coworkers 
(2002) showed a similar need for secondary procedures after open (16 %) and endovascular repair 
(17 %). All problems cannot be treated endovascularly, and in some EVAR patients when 
secondary or even further re-interventions are attempted, conversion to open repair is needed 
(Verhoeven et al. 2004). 
 
Conversions 
 
Conversion is defined as a laparotomy with removal of the endograft followed by aneurysmal repair 
by insertion of a prosthesis (Verhoeven et al. 2004). Primary conversion from endovascular to open 
repair is performed at the original operation, while secondary conversion is performed on a 
subsequent occasion. Secondary conversions may be urgent (i.e. precipitated by aneurysm rupture 
or its suspicion) or elective (Chaikof et al. 2002b). Factors increasing the risk for conversions 
include a short, wide, angulated infrarenal aortic neck and large aneurysm, enlargement of the 
aneurysm during the follow-up, proximal, midgraft and side branch-related endoleak, device 
migration, and lack of experience among the team performing the procedure (Buth et al. 2002, 
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Cuypers et al. 2000, Sternbergh et al. 2002). In a meta-analysis of outcome after EVAR conversion 
was performed in the perioperative period in 5 % of patients, and in 1.4 % annually thereafter 
(Walschot et al. 2002). In the EUROSTAR database, the cumulative rate of conversions was 11.7 % 
at 4 years (Buth et al. 2002). 
 
Conversion to an open procedure has been performed when endovascular treatment has failed: 
previously endovascularly treated aneurysm have ruptured, or there have been complications 
attributed to endovascular repair, which could not have been corrected otherwise (Verhoeven et al. 
2004). These complications include access problems, failed assembly, device malfunction during 
deployment, aortic dissection, limb occlusion, disconnection of stent-graft modules, aneurysm 
growth with or without persistent endoleak (endotension), and migration, which have often been 
unsuccessfully treated with secondary endovascular procedures, and infection (Cuypers et al. 2000, 
Heikkinen et al. 1999, Jacobowitz et al. 1999, Lipsitz et al. 2003, Terramani et al. 2003, Verhoeven 
et al. 2004). Conversions have been described as complex, hazardous and unwarranted procedures 
after reports of high mortality rates  (Table 2). Both primary and secondary conversions carry a high 
mortality rate when performed for ruptured AAA (Cuypers et al. 2000). Some patients, with 
complications, who remain untreated due to the high risk of conversion procedures, die suddenly of 
unknown causes. This may deceive the overall results of endovascular treatment (Gilling-Smith et 
al. 2000, Liewald et al. 2001b). 
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Table 2. Conversion rate and 30-day mortality in the litterature. 
 
Author Publication 
year 
No. of 
patients 
Follow-up 
period (months, 
mean) 
Conversions 
N (%) 
Mortality 
N (%) 
May et al. 1997 1997 113 n.a. 18 (16 %) 3 (17 %) 
Jacobowitz et al. 1999 1999 669 40 46 (7 %) 4 (9 %) 
Tiesenhausen et al. 2000 2000 67 15 (13 %) n.a. 
Liewald et al. 2001b 2001 130 20 5 (4 %) n.a. 
Ohki et al. 2001 2001 239 75 5 (2 %) n.a. 
Buth et al. 2002 2002 3529 n.a. 149 (4 %) (19 %) ∗ 
Bockler et al. 2002 2002 520 23 37 (7 %) n.a. 
Chaikof et al. 2002a 2002 236 17 10 (4 %) n.a. 
Sampram et al. 2003 2003 703 12 11 (9 %) (18 %) ∗ 
May 2003 2003 190 n.a. 45 (24 %) n.a. 
Terramani et al. 2003  2003 319 n.a. 20 (6 %) 1 (5 %) 
Lipsitz et al. 2003 2003 386 n.a. 11 (3 %) 2 (18 %) 
Becquemin et al. 2004 2004 250 n.a. 11 (4 %) 0 
Verhoeven et al. 2004  2004 306 36 9 (3 %) 0 
 
n.a. = not available. ∗ = a subgroup of secondary conversions. 
 
Results of studies comparing open and endovascular treatment 
 
Various non-randomised studies have compared endovascular and open repair of AAA. The rates of 
mortality, morbidity, endoleaks, secondary interventions, conversions and ruptures in these studies 
vary considerably (Hinchliffe and Hopkinson 2003). The mortality rates were similar in the early 
reports, but EVAR was found beneficial in reducing the length of hospital stay, duration of 
intensive care admission, and the blood loss of the patient. Sucsequently, EVAR has been shown to 
also lower the in-hospital mortality and complication rates (Garcia-Madrid et al. 2004, Longo and 
Eskandari 2004). Despite these beneficial results of EVAR, the long-term results have remained 
uncertain, especially due to the lack of randomised, controlled studies (Akert et al. 2004). Several 
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studies of that kind have been started, but no mid- or long-term results have been available prior to 
June 2005, when the mid-term results of EVAR trials 1 and 2 were published. 
 
The EVAR 1 trial is the first randomised controlled study comparing open and endovascular 
treatment to present mid-term results of mortality, durability, health-related quality of life (HRQL), 
and costs for patients. The recruitment began in September 1999 in the UK (Brown et al. 2004). 
After enrolling 1082 patients, of which 543 were treated endovascularly and 539 with open repair, 
the results after four years of randomisation and a median follow-up of 2.9 years showed no 
difference between the groups in all-cause mortality, but there was a persistent 3 % reduction in 
aneurysm-related deaths in the EVAR group. On the other hand, EVAR offered no advantage with 
HRQL, was more expensive, and lead to a greater number of complications (41% versus 9%) and 
reinterventions than open repair (EVAR trial participants 2005a). 
 
EVAR trial 2 is a randomised controlled trial concomitant with EVAR 1 to compare EVAR and 
conservative treatment in patients unfit for open repair. Four years after randomisation there were 
166 patients in the EVAR group and 172 patients in the group of best medical treatment. There was 
no significant difference between the groups for all-cause mortality, and EVAR was associated with 
substantially increased cost and a need for continued surveillance and reinterventions (EVAR trial 
participants 2005b). 
 
The Dutch Randomised Endovascular Aneurysm Management (DREAM) trial is a randomised trial 
comparing open and endovascular treatment of AAA patients considered suitable for both types of 
treatment (Prinssen et al. 2002). The trial is more limited than the EVAR trials with 351 randomised 
patients. The first report suggested a 3.4 % reduction in operative mortality with EVAR (Prinssen et 
al. 2004c) but after two years of randomisation the perioperative survival advantage was not 
sustained (Blankensteijn et al. 2005). The results of quality of life (QoL) assessments in the first 
postoperative year have been published in February 2004. The results showed some QoL advantage 
for EVAR in the early postoperative period, but later the QoL was better in the patients with open 
repair (Prinssen et al. 2004a). In December 2004 were published the results regarding sexual 
dysfunction in both groups after the same follow-up period. The results showed an impact on sexual 
function in both groups in the early postoperative period. The recovery to preoperative levels was 
faster in the EVAR group, but after 3 months there was no difference between the groups (Prinssen 
et al. 2004b). 
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Moreover, the randomised ACE trial in the Netherlands and the OVER trial in the USA are 
underway (EVAR trial participants 2005a). 
 
Prospective registries provide valuable information in endovascular aneurysm repair. Although 
long-term data is available, these registries are not comparing EVAR to open repair in a 
randomised, controlled manner. Two of the largest registries are the EUROSTAR registry and the 
Registry of Endovascular Treatment of abdominal aortic Aneurysms (RETA) (Harris and Buth 
2004, Thomas et al. 2001, Thomas et al. 2005). 
 
SEQUELAE TO ANEURYSM REPAIR 
 
Changes in renal function during AAA repair 
 
Open abdominal aortic aneurysm repair requiring aortic cross-clamping induce rather frequently (up 
to 14 %) transient renal insufficiency, which fortunately seldom is so severe, that dialysis is needed 
(Cherr and Hansen 2001). Acute renal failure is characterized by high mortality, especially in 
patients with multiple organ failure (Johnston 1989, Nowicki et al. 2004). The degree of renal 
failure is dependent on the preoperative renal function, the cross-clamping site, and usually results 
from acute tubular necrosis (Gelman 1995, Johnston 1989, Powell et al. 1997). Even infrarenal 
cross-clamping is associated with an increase in renal vascular resistance, and a decrease in renal 
blood flow. Adverse renal haemodynamic changes may persist for several hours after declamping of 
the aorta (Backlund et al. 2000, Gamulin et al. 1984, Gelman 1995).  
 
Changes in renal blood flow during and after aortic clamping are considered to result from 
activation of renin-angiotensin system or sympathetic nervous system, ischemia-reperfusion injury 
with myoglobin release from the lower extremities, turbulent blood flow in the renal arteries or 
possible embolic complications (Gamulin et al. 1986, Welch et al. 1994, Wijnen et al. 2001). 
Hypotension, hypovolemia and the use of anesthetic or antimicrobial drugs may also lead to 
deterioration in renal function (Backlund et al. 2000, Cherr and Hansen 2001, Higuchi et al.  1995). 
An adequate fluid replacement regimen have been shown to decrease the rate of renal complications 
(Cherr and Hansen 2001, Gelman 1995, Rashid et al. 2004, Welch et al. 1993). 
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During EVAR aortic cross-clamping is not needed, though the aorta is occluded for a short period 
of time during ballooning of the infrarenal landing zone. Lower extremity ischemia may still occur, 
as large introducers can occlude iliac or femoral arteries for a substantial time period during the 
procedure (Wijnen et al. 2001). Endovascular devices with suprarenal fixation may also induce 
thromboembolic complications to renal arteries (Mehta et al. 2004). In contrast to open aneurysm 
repair, a considerably high amount of contrast media is used during EVAR. Administration of 
contrast media is shown to be able to cause a dose-dependent renal insufficiency by altering renal 
hemodynamics or by a direct toxic effect on renal tubular cells (Cherr and Hansen 2001, Surowiec 
et al. 2004, Tepel et al. 2000). Contrast media-induced renal dysfunction is best avoided by proper 
hydration of the patient (Solomon et al. 1994, Tepel et al. 2000). 
 
Studies comparing renal responses in open and endovascular AAA repair  
 
Transient renal failure requiring dialysis has been reported after endovascular repair of AAA (White 
et al. 1996). Using albumin/creatinine ratio in urine as a marker of glomerular function Wijnen et al 
found mild, short-lasting damage to the kidney which was less compared to open surgery (Wijnen et 
al. 2001). They concluded that the difference between open and endovascular repair could be 
induced by a combination of ischemia reperfusion injury and surgical trauma during open AAA 
repair.  
 
Suprarenal fixation has been considered a risk for renal function, but studies comparing supra- and 
infrarenal fixation have not shown any significant difference in renal function tests between these 
two methods (Mehta et al. 2004, Surowiec et al. 2004). However, in a recent retrospective analysis, 
a decrease of creatinine clearance was found in the first year both after supra- and infrarenal 
fixation of endografts, and the magnitude of decrease was greater in patients with renal impairment 
when suprarenal fixation was used (Alsac et al. 2005). 
 
Markers of renal dysfunction 
 
 
N-acetyl-β-D-glucosaminidase (NAG), a lysosomal enzyme, is located predominantly in the renal 
proximal tubuli. It is a very sensitive indicator of renal injury (Wellwood et al. 1975). Damage of 
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the proximal tubular cells, which may also be reversible, is shown to result in an increase in the 
excretion of NAG into urine (Backlund et al. 2000, Higuchi et al. 1995, Laisalmi et al. 2001).  
 
Cystatine C is a proteinase inhibitor that is produced in all nucleated cells. It is freely filtered in the 
proximal renal glomeruli and reabsorbed and metabolised in the proximal tubule. It is a sensitive 
marker on glomerular filtration rate and independent on height, gender, age and muscle mass of the 
patient (Filler et al. 2005, Fliser and Ritz 2001). 
 
Serum creatinine and creatinine clearance are less sensitive markers of renal dysfunction. They are 
also dependent on the muscular mass of the patient (Higuchi et al. 1995, Shlipak et al. 2005). 
 
Blood loss  
 
Major blood loss during AAA repair is an important determinant of postoperative complications 
(Ho et al. 2004). In most studies comparing open and endovascular AAA repair, blood loss has been 
significantly reduced during endovascular repair (Garcia-Madrid et al. 2004, White et al. 1996, 
Wijnen et al. 2001). 
 
Changes in hemostasis 
 
Patients with AAA have chronic upregulation of coagulation and fibrinolysis (Aramoto et al. 1994, 
Holmberg et al. 1999a, Oba et al. 1995, Yamazumi et al. 1998). Open aneurysmal repair further 
increases these phenomena (Holmberg et al. 1999a). An inhibition of systemic fibrinolysis 
accompanied with increased thrombin generation have also been shown, which may contribute to 
myocardial infarctions and thromboembolisms seen in these patients (Adam et al. 1999). The 
influence of surgery to coagulation and fibrinolysis have been explained by the operative trauma 
and stress reaction of the patient, blood loss and by the ischemia-reperfusion injury following aortic 
clamping and declamping (Holmberg et al. 1999a). 
 
Aortic clamping during open AAA surgery induces an ischemia-reperfusion injury, which in 
addition to inflammatory response may cause a hypercoagulable state and a risk of thrombotic 
complications (Bradbury et al. 1997, Holmberg et al. 1999a, Levi 2003). In some studies the 
 27 
  
endotoxemia following ischemia and reperfusion of the gut is considered the main stimulus for 
these phenomena (Holzheimer et al. 1999, Welch et al. 1995). 
 
Activation of the inflammatory system 
 
Injurious stimuli to the human body cause an inflammatory response. During this inflammatory 
response, transvascular shift of fluids, plasma proteins and leukocytes occur. Activation of platelets 
and coagulation proteins is induced in order to maintain hemostasis. These processes aim to 
neutralise the injurious stimulus, limit tissue injury and initiate healing (Tan et al. 1999).  
 
Conventional AAA repair requiring laparotomy, aortic cross-clamping and subsequent ischemia-
reperfusion injury initiate a systemic inflammatory response. This response is thought to be mainly 
mediated by oxygen-derived free radicals, and may lead to increased vascular permeability, 
pulmonary oedema, lung injury and renal failure (Boyle et al. 2000, Groeneveld et al. 1997, 
Kretzschmar et al. 1996, Norwood et al. 2004a, Syk et al. 1998, Thiagarajan et al. 1997). Aortic 
surgery also activates the complement system, release cytokines, kinin, histamine and induce 
neutrophil recruitment and degranulation (Groeneveld et al. 1997, Norwood et al. 2004b). Pro- and 
anti-inflammatory cytokines and adhesion molecules are considered important mediators of the 
systemic inflammatory reaction (Swartbol et al. 1996a). This reaction initially neutralises the 
trauma stimulus and initiates healing and repair, but if the circulating amount of cytokines is higher 
than required, an abnormal inflammatory response can lead to systemic inflammatory response 
syndrome (SIRS) and finally to multi-organ failure (MOF), which is characterized by a critically ill 
patient requiring organ support (Bown et al. 2001, Bown et al. 2004, Norwood et al. 2004b, 
Swartbol et al. 2001). It is hypothesised that EVAR would initiate a lesser systemic inflammatory 
reaction due to a substantially shorter aortic clamping time and lesser intra-abdominal manipulation 
compared to open surgery (Thompson et al. 1996). 
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Inflammatory system 
 
Complement system 
 
The complement system comprises of several plasma proteins, which act as mediators in 
inflammatory reactions, bacterial lysis, mast cell degranulation and neutrophil chemotaxis. The 
degree of complement activation has been shown to correlate with the cross-clamp time during 
aortic surgery (Bengtson et al. 1987, Norwood et al. 2004b). 
 
Kinins 
 
Kinins are plasma-derived mediators of inflammation. Bradykinin, the main product of kinin 
pathway, increase vascular permeability, cause arterial dilatation and pain (Norwood et al. 2004b). 
 
Endothelium 
 
Vascular endothelium is an important regulatory organ in immunity and hemostasis. It is normally 
in an unactivated state, but at sites of injury and inflammation, the endothelium becomes activated 
by inflammatory cytokines released in response to the injury. Activated endothelium express pro-
inflammatory molecules, adhesion molecules and recruits leukocytes and platelets at sites of 
inflammation, thus inducing platelet thrombosis and leukocyte accumulation (Tan et al. 1999). 
Endothelial activation has also been observed during AAA surgery. Elevated levels of intercellular 
adhesion molecule-1 (ICAM-1) suggest increased endothelial activation in AAA patients in shock 
and in non-survivors of ruptured AAA (Norwood et al. 2004b). 
 
 
 
 
 
 29 
  
Adhesion molecules 
 
Leucocyte-endothelial cell adhesion molecules (CAM) mediate the interactions between circulating 
leucocytes, platelets and endothelium. At sites of injury or inflammation this interaction leads to 
leucocyte recruitment into tissues and thrombosis. CAM are classified in four families: the 
selectins, integrins, mucin-like CAM and the immunoglobulin superfamily (Tan et al. 1999). 
 
Selectins 
 
Selectins are expressed by leucocytes, activated endothelium and platelets. They are transmembrane 
glycoproteins, which mediate the initial attachment and rolling of leucocytes in postcapillary 
venular endothelium at sites of injury or inflammation (Furie and Furie 1995, Furie et al. 2001, 
McIntyre et al. 1997, Modur et al. 1997, Palabrica et al. 1992, Tan et al. 1999, Tedder et al. 1995, 
Yang et al. 1999).  
 
The selectin family consists of three members: L-selectin is expressed on leucocytes, P-selectin in 
endothelial cells and platelets and E-selectin, which is expressed exclusively in activated vascular 
endothelial cells (McIntyre et al. 1997, Tedder et al. 1995). P–selectin is sequestrated in 
intracellular storage granules, and inflammatory mediators like histamine and trombin induce a 
translocation of P-selectin to the surface of platelets and vascular endothelial cells (Tan et al. 1999), 
where it mediates the interaction of leucocytes with platelets and stimulated endothelium in the 
region of tissue injury (Furie and Furie 1997, McIntyre et al. 1997, Palabrica et al. 1992, Tedder et 
al. 1995). P-selectin expression leads to capture of leucocytes in the area of tissue injury, thus 
playing a critical role in inflammation and thrombogenesis (Furie and Furie 1995; Furie et al. 2001). 
P-selectin expression have been shown to be upregulated both in AAA and in peripheral arterial 
disease (PAD) patients (Blann et al. 1998, Itoh et al. 1995) 
 
Immunoglobulin superfamily 
 
These cell-surface proteins mediate leucocyte-endothelial adhesion, and are divided into five 
members: intercellular adhesion molecule-1 (ICAM-1), ICAM-2, ICAM-3, vascular cell adhesion 
molecule-1 (VCAM-1) and platelet-endothelial cell adhesion molecule-1 (PECAM-1). ICAM-1 is 
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expressed in vascular endothelium, some leucocytes, but not in neutrophils. The expression at 
endothelium is upregulated by endotoxin and inflammatory cytokines (Tan et al. 1999). 
 
Cytokines  
 
The alterations in hemodynamic, metabolic and immune responses triggered by surgical injury or 
infection are largely mediated by endogenous mediators referred as cytokines. Cytokines are 
polypeptides or glycoproteins produced by diverse cell types at the site of injury or by systemic 
immune cells and function predominantly by means of paracrine and autocrine mechanisms. They 
are bioactive at low consentrations. This way cytokines differ from hormones, which are produced 
in specialised tissues, and influence by endocrine routes. Cytokines mediate local inflammatory 
response, trigger chemotaxis and activate leukocytes, T cells and natural killer cells (NK cells) and 
regulate the production and activity of other cytokines, which may act in proinflammatory or anti-
inflammatory way (Fong et al. 1990, Lin et al. 2000, Syk et al. 1998). Those cytokines clearly 
promoting inflammation are called proinflammatory cytokines, while those suppressing 
inflammatory activity are called anti-inflammatory cytokines. On the other hand, this categorization 
is dependent on the biological process involved, and some cytokines can have both pro- and anti-
inflammatory functions (Dinarello 2000, McIntyre et al. 1997).  
 
Cytokines mediate and direct the inflammatory response to sites of infection or injury. They have 
beneficial properties in injury, such as healing of the wounds, but exaggereted or prolonged 
production of proinflammatory cytokines can lead to systemic changes seen in septic shock and 
persistently exaggerated production can contribute to end-organ injury, leading to SIRS, MOF, and 
death. However, the presence of anti-inflammatory cytokines counter-regulate some of these 
responses (Fong et al. 1990, Lin et al. 2000). Therefore, it is thought that a balance between the 
effects of pro- and anti-inflammatory cytokines determine the outcome of the patient (Dinarello 
2000). Cytokines play an essential role in regulating the amplitude and duration of the inflammatory 
process (Swartbol et al. 2001). Interleukin 1 β (IL-1β), interleukin 6 (IL-6) and tumor-necrosis 
factor α (TNF-α) are considered the major mediators of the acute phase response in humans (Bone 
1996, Lin et al. 2000, Swartbol et al. 1996b, Tan et al. 1999). 
 
There are at least 18 cytokines called interleukins, while other cytokines have retained their original 
description like tumor-necrosis factor (TNF) (Dinarello 2000). 
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Tumor-necrosis factor (TNF) 
 
TNF-α, a proinflammatory cytokine, originates from a variety of myeloid cells, such as blood 
monocytes, pulmonary and peritoneal macrophages and neutrophils. The half-life of TNF-α is 
short, approximately 14 to 18 minutes. It has catabolic effects on peripheral tissues but anabolic for 
hepatocytes. It is a growth factor, with a capacity to stimulate fibroplastic proliferation and 
formation and remodelling of wounds (Fong et al. 1990). Surgical or traumatic injury to the 
abdominal viscera or ischemia-reperfusion injury trigger the release of TNF-α , which mediate 
cellular responses by endothelial activation, nitric oxide synthesis, neutrophil release, neutrophil 
and macrophage activation and chemoattraction. Together with proinflammatory interleukin IL-6 
TNF-α upregulate the expression of adhesion molecules, influence the generation of other 
inflammatory mediators and homeostatic responses such as acute-phase protein production (Lin et 
al. 2000). These responses can lead to fever, tachycardia, a fall in blood pressure and peripheral 
perfusion, shock, activation of coagulation, sequestration of leukocytes in the lungs and possibly 
acute respiratory distress syndrome (ARDS). Corresponding changes in the kidneys and 
myocardium may lead to multiple organ dysfunction syndrome (MODS) (Linet al. 2000, Norwood 
et al. 2004, Syk et al. 1998). 
 
 
Interleukin-1 (IL-1) 
 
Mainly proinflammatory IL-1 is released predominantly by blood monocytes, activated 
macrophages and endothelial cells in response to mitogenic and antigenic stimulation. There are 
two species of IL-1: IL-1α and IL-1β. IL-1α influences via cellular contacts in cell membrane, 
whereas IL-1β is detectable in circulation. The half-life in circulation is very short, approximately 
six minutes. IL-1 has a synergistic role with TNF-α in initiating hemodynamic decompensation. IL-
1 acts on a variety of immunologic cells, accelerates T-cell proliferation, induces a release of 
granulocytes from bone marrow and an influx of them into an inflammatory site. It also induces 
inflammatory febrile response to injury by stimulating a local prostaglandin release in the anterior 
hypothalamus. IL-1 is involved in connective tissue and bone remodelling during injury and 
inflammation, and has major effects on the balance of proteins in hepatic and peripheral tissues. 
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These influences are beneficial during injury, but during simultaneous TNF-α release, the resulting 
increase of permeability of endothelial cells can lead to excessive margination of activated 
neutrophils into pulmonary epithelium and may contribute to pulmonary failure (Fong et al. 1990, 
Lin et al. 2000). 
 
Interleukin-6 (IL-6) 
 
IL-6 has both proinflammatory and anti-inflammatory actions, but it has mainly proinflammatory 
role. TNF-α and IL-1 induce IL-6 release from virtually all cells and tissues after injury or blood 
loss (Bone 1996, Shenkin et al. 1989). The levels of IL-6 peak between four and six hours after 
injury and may persist for ten days. The levels of circulating IL-6 are proportional to the extent of 
tissue injury during an operation (Cruickshank et al. 1990). IL-6 induces neutrophil activation, 
differentiation of lymphocytes, tissue factor expression and mediates the hepatic acute-phase 
response during injury and inflammation. These actions are beneficial by enhancing immune 
function and acute phase protein synthesis. IL-6 acts also as an endogenous pyrogen (Bouchard and 
Tracy 2003, Fong et al. 1990, Lin et al. 2000). 
 
Interleukin-10 (IL-10) 
 
IL-10 is mainly anti-inflammatory and it is capable of regulating the inflammatory reaction by 
modulating TNF-α activity (Lin et al. 2000). 
 
Cross-talk between inflammation and coagulation  
 
 
Coagulation and fibrinolytic activity are upregulated in AAA patients. These activations are further 
increased during surgery when proinflammatory mediators are present. Coagulation proteases 
induce also proinflammatory mediators, which in turn have procoagulant activity. These 
interactions amplify the cascade towards disseminated intravascular coagulopathy (DIC), and 
possible multi-organ failure (MOF) (Levi 2003). 
 
Acute inflammation results in systemic activation of the coagulation system. Cytokines activate 
tissue factor in mononuclear cells, and tissue-factor mediated activation of coagulation has been 
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considered the principal initiator of inflammation-induced thrombin generation. However, it is 
apparent, that endothelial cells, which respond to the cytokines expressed by leucocytes, can release 
cytokines and express adhesion molecules themselves resulting in promotion of the inflammatory 
and coagulation responses (Levi 2003). The binding of P-selectin to monocyte receptors leads to 
activation of proinflammatory and prothrombotic pathways, including the expression of tissue 
factor (Bouchard and Tracy 2003, Furie and Furie 1997, Furie et al. 2001). TNF-α and IL-1 also 
increase thrombin generation by down-regulating the expression of thrombomodulin, thus limiting 
the activation of protein C. They also inhibit the fibrinolytic system by increasing plasminogen 
activator-inhibitor 1 (PAI-1)- synthesis and decreasing plasminogen activator synthesis. 
Coagulation activation also has effects on the inflammatory mechanisms: Factor Xa, thrombin and 
tissue factor-factor VIIa complex have all proinflammatory activites, and thrombin induce 
production of IL-6 and IL-8 in endothelial cells. Activated protein C in turn has anti-inflammatory 
effects; it decreases the levels of IL-6 (Levi 2003). 
 
Results of the studies comparing inflammation and coagulation in open and endovascular 
repair 
 
A systemic inflammatory response has been found during open AAA repair, mainly involving 
elevated IL-6 levels (Bown et al. 2001, Groeneveld et al. 1997, Holmberg et al. 1999b, Lau et al. 
2001, Parsson et al. 1997, Soong et al. 1997, Swartbol et al. 1996b).  Several studies have 
demonstrated an inflammatory response also with endovascular AAA repair (Boyle et al. 2000, 
Elmarasy et al. 2000, Galle et al. 2000, Hayoz et al. 1997, Morikage et al. 2000, Odegard et al. 
2000, Parodi et al. 2001, Rowlands and Homer-Vanniasinkam 2001, Schumacher et al. 1997, 
Swartbol et al. 1996a, Sweeney et al. 2002, Syk et al. 1998, Thompson et al. 1996), which has also 
been attributed to the fever reaction, leucosytosis and elevated C-reactive protein levels seen in 
many of these patients postoperatively (Blum et al. 1997, Galle et al. 2000). 
 
It was initially supposed that a lesser degree of tissue manipulation and lesser surgical trauma 
would protect the patient from enhanced inflammatory response during endovascular repair. A 
number of studies have confirmed this (Swartbol et al. 2001), but in some studies the inflammatory 
response has been more pronounced during endovascular repair (Morikage et al. 2000), or differed 
from open repair by means of elevated circulating TNF-α values (Norgren and Swartbol 1997, 
Swartbol et al. 1996a). 
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The systemic reaction related to endovascular repair may be a consequence to the manipulation in 
the aneurysm and aorta (Morikage et al. 2000), or in the mural thrombus, which is shown to contain 
IL-6 (Galle et al. 2000, Swartbol et al. 1998). It is also postulated that the reaction could be 
triggered by the biomaterials used in the endovascular grafts (Galle et al. 2000). 
 
As contrast media is used only during endovascular repair, it is hypothesised that the inflammatory 
response following endovascular repair is caused by radiographic contrast media based on the 
timing of leucocyte and platelet activation (Odegard et al. 2000). 
  
The results of some studies comparing open and endovascular repair in these complex inflammatory 
systems do, however, have contradictory results (Morikage et al. 2000). This may be a result of 
differences in the timing of the laboratory samples taken (Swartbol et al. 2001). 
 
It is also hypothesised that bacteremia following manipulation of the mural thrombus would initiate 
the inflammatory reaction seen during endovascular repair, as the mural thrombus is shown to be 
contaminated by bacteria in up to 25 % of patients (van der Vliet et al. 1996). 
 
Swartbol and colleagues have summarised the results of most studies comparing open and 
endovascular repair of AAA in their meta-analysis (Swartbol et al. 2001). Their conclusion was that 
cytokine response is more regularly seen during open repair. The levels of TNF-α reflect the 
clinical outcome of the patient and IL-6 correlates with the amount of surgical trauma. They also 
found that the timing of blood samplings is important as major changes were seen within first hours 
after stent-graft implantation. By the finding by Swartbol and colleagues that clinical reactions 
closely related to SIRS were absent in patients with small or no intra-aneurysmal thrombus they 
advised avoidance of manipulation and fragmentation of the intra-aneurysmal thrombus and 
endothelium, which may lead to a release of proinflammatory cytokines and a profound 
inflammatory reaction. However, in some studies a profound elevation of cytokine levels was 
observed after endovascular procedures, but without association with other clinical parameters 
except long-lasting temperature increase (Swartbol et al. 2001). 
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The role of contrast media in inflammation and coagulation 
 
Contrast media have several potential side-effects, including pulmonary oedema, changes in 
myocardial function, ventricular arrhytmia and anaphylactic reactions (Rasmussen 1998). In 
addition, contrast media also have effects on the coagulation, fibrinolytic and complement systems, 
and may alter thrombocyte function, cause endothelial lesions and upregulate P-selectin expression, 
adhesion to neutrophils and increase PAI-1 and TNF-α expression (Rasmussen 1998, Till et al. 
1978). The side-effects have been attributed to the ionic nature or high osmolality of the contrast 
media used (Akagi et al. 1991, Laffan et al. 1997, Rasmussen et al. 1992, Rasmussen 1998). 
 
In in vitro-studies, contrast media have been shown to inhibit chemotaxis, neutrophil adherence and 
phagocytosis (Rasmussen 1998). Non-ionic contrast media are considered to cause profound 
platelet activation and degranulation (Chronos et al. 1993, Scheller et al. 2001), they may also 
induce upregulation of P-selectin expression, adhesion of leukocytes to endothelial cells and 
promote the production of inflammatory cytokines (Abeyama et al. 1995, Blann et al. 2001), while 
ionic contrast media may impair the binding of fibrinogen to glycoprotein IIb/IIIa (GP IIb/IIIa) 
receptor during platelet aggregation, inhibit thrombin generation in plasma (Scheller et al. 2001) 
and suppress complement activity (Mikkonen et al. 1997). In vivo-studies have mainly concentrated 
in the influence of different contrast media in stent occlusions after coronary interventions. Non-
ionic contrast media are thought to have less side effects than ionic contrast-media, but there is 
evidence that ionic contrast media would protect the patient from thrombotic complications, though 
the results of different studies are controversial (Albanese et al. 1995, Laffan et al. 1997, Ogawa et 
al. 2001, Scheller et al. 2001).  
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AIMS OF THE PRESENT STUDY  
 
Endovascular repair is a less invasive treatment method of AAA. It is expected that EVAR would 
result in lesser morbidity and mortality than open repair. However, the high complication rates and 
increased need for re-interventions observed during the follow-up of endovascularly treated patients 
question the durability of EVAR. The aim of this study was to assess how EVAR has fulfilled some 
of the expectations, by investigating the short-time results of EVAR in Finland, the mid-term results 
and complications of EVAR at the Helsinki University Central Hospital and to compare the effects 
of EVAR and open abdominal aortic aneurysm repair in renal function, inflammation and 
coagulation. 
 
The aims were to assess: 
 
1) The results of EVAR in Finland. 
2) Does EVAR, compared to open surgery, protect the kidneys from renal dysfunction. 
3) The outcome of conversion procedures after compromised EVAR. 
4) Does EVAR activate less prothrombotic and inflammatory interactions than open repair. 
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MATERIALS AND METHODS  
 
The study protocols of this thesis were approved by the Ethics Committee of the Helsinki 
University Central Hospital. All patients participating the prospective studies (II and IV) gave their 
informed consent. 
 
Study I. 
 
Between November 1996 and November 2000 a total of 218 abdominal aortic aneurysms, 
pseudoaneurysms or dissections and 11 thoracic aortic aneurysms were treated using endovascular 
stent graft in five Finnish centres. All eligible patients were included, regardless of the outcome of 
the procedure (Table 3). The data was collected prospectively in all centres by the surgeon or 
interventional radiologist involved. The data was afterwards pooled to cover the activity of the 
whole country. The results were compared to the results of the large multicenter EUROSTAR 
registry with 2464 patients enrolled during the same time period 1996-2000. 
   
There were 196 male and 33 female patients. The mean age was 70 years (range 33-86 years). 
Altogether 12 patients were considered to be unfit for conventional open surgery due to associated 
cardiac, pulmonary, renal or other disease. 
 
Table 3. Patient characteristics and study period involved in study I. 
 
No of pts     229  
Males 196 
Females 33 
Mean (range) age (years) 70 (33-86) 
Max AAA diameter (range) (mm) 55 (30-105) 
Mean (range) follow-up time (months) 14 (0-41) 
Study period 1996-2000 
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Study II. 
 
In a prospective, non-randomised study the effect in renal function was compared between EVAR 
open AAA repair. 24 patients with infrarenal aortic aneurysms treatable with either method were 
included in the study. There were 15 patients in the EVAR and nine patients in the open repair 
group (Table 4). The treatment method used was decided according to the preference of the 
radiologist and the surgeon involved. One patient declined endovascular treatment. Patients with a 
short infrarenal aortic neck and those with thrombus in the infrarenal neck were excluded. All the 
aneurysms had maximum diameter of 55 mm or more or had been growing in ultrasound 
surveillance. Seven Zenith, six Talent and two Vanguard devices were used in the endovascular 
group. 
 
Table 4. Patient characteristics, preoperative and surgical data (mean (range) or number of patients) 
∗ p < 0.05. 
 
 OPEN 
(n=9) 
EVAR 
(n=15) 
Age (range) (yr) 70 (65-77) ∗ 75 (64-83) 
Female/male 2/7 2/13 
Weight (range) (kg) 80 (64-105) 79 (57-97) 
ASA-group 1 0 0 
ASA-group 2 0 1 
ASA-group 3 9 11 
ASA-group 4 0 3 
Aneurysm size (range) (mm)  66 (58-74) ∗ 58 (49-78) 
Radio-contrast (ml/kg) 0 3.1 (1.4-4.9) 
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Study III. 
 
Between November 1996 and February 2004 518 patients with infrarenal abdominal aortic 
aneurysm were treated electively in the Helsinki University Central Hospital. 110 (21 %) of those 
were treated endovascularly. The results of these patients together with the results of secondary 
procedures, especially conversion procedures were evaluated. 
 
The mean follow-up time was 14 months with a range of 0 to 41. The median age of the patients 
was 74 years (range, 47-87), and the median maximal diameter of the aneurysm 59 mm (range 34-
105) (Table 5). All the patients were followed up with a contrast-enhanced computed tomography 
and plain x-rays at 1, 6, and 12 months, and annually thereafter. In case of a death of unknown 
reason (six patients), the data was received from a national database (The Statistics Finland). 
 
Table 5. Patient characteristics and study period involved. 
 
No of pts 110 
Males 93 
Females 17 
Mean age (range) (years) 74 (47-87) 
Max AAA diameter (range) (mm) 59 (34-105) 
Median (range) follow-up time (months) 29 (0-76) 
Study period 1996-2004 
 
 
Study IV. 
 
The impact of intra-aneurysmal thrombus mass and surgery on inflammation and coagulation was 
compared between EVAR and open AAA repair. Thirty-two consecutive patients were recruited, 17 
were treated endovascularly and 15 with open repair (Table 6). The mode of treatment was chosen 
according to radiographic anatomy: the endovascular approach was used when the anatomy of the 
patients aneurysm fulfilled sufficiently the criteria to securely isolate the aneurysm from arterial 
pressure. 
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There was no difference between the groups in age, gender, weight or ASA-classification.  
Exclusion criteria were: moderate peripheral arterial occlusive disease (ankle-brachial index < 
0.70), any systemic inflammatory disease, insulin-dependent diabetes mellitus, previous trauma or 
surgery within prior two months, malignancy and use of steroids or warfarin. 
 
Table 6. Patient characteristics, preoperative and surgical data (mean (range) or number of patients) 
∗ p < 0.05. 
 
 OPEN 
(n=15) 
EVAR 
(n=17) 
Age (yr) 72 (65-78) 74 (56-83) 
Female/male 3/15 2/17 
Weight (kg) 75 (57-105) 79 (57-97) 
ASA-group 1 0 0 
ASA-group 2 2 3 
ASA-group 3 9 11 
ASA-group 4 4 3 
Intra-aneurysmal thrombus  (ml)  76 (21-206) ∗ 42 (15-101) 
Aneurysm size (mm)  64 (52-77) ∗ 57 (48-78) 
Radio-contrast (ml/kg) 0 3.0 (1.4-4.9) 
Blood loss (ml)  2033 (500-4300) ∗ 756 (0-2300) 
 
 
RENAL FUNCTION (II) 
 
Renal function was assessed by measuring U-NAG / crea (Urinary N-acetyl-β-D-glucosaminidase - 
creatinine ratio) preoperatively, at the end of surgery, eight and 24 hours postoperatively. Other 
renal function tests included serum creatinine, urine creatinine clearance and serum cystatin C 
measurements pre- and 24 h postoperatively. For the creatinine clearance measurements urine was 
collected 48 hours pre- and postoperatively. Plasma renin activity was measured before surgery, at 
the end of surgery, eight hours and 24 hours postoperatively. 
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INFLAMMATION AND COAGULATION (IV) 
 
The following plasma markers were analysed preoperatively, at one, two, three, four and seven days 
and at three months postoperatively: Markers of coagulation activity: prothrombin fragment 1+2 (F 
1+2), thrombin-antithrombin III complex (TAT), fibrinogen (P-Fibr), markers of fibrinolysis: D-
dimer, tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor (PAI)-1 
antigens (Ag), the levels of proinflammatory cytokines interleukin 6 (IL-6) and interleukin 1 β (IL-
1β) and anti-inflammatory interleukin 10 (IL-10), as well as soluble adhesion molecules P-Selectin 
and ICAM-1 together with C-reactive protein (CRP) and aminoterminal peptide of procollagen (S-
PIIINP), a marker of collagen turnover. 
 
BLOOD SAMPLING AND PROCESSING (IV) 
 
Cubital venous blood was collected in 3.8 % citrate preoperatively, at the first postoperative 
morning, at two, three, four and seven days, and three months postoperatively. Within 30 minutes 
after blood sampling the plasma was separated by centrifugation and stored at – 85 °C. 
 
ASSAYS (II AND IV) 
 
Urine NAG was determined from spot samples using using 3-cresonsulphonphtalein-N-acetyl-b-
glucosamine as a substrate. The method was adapted to a Kone Specific random acces analyzer. 
Kinetic follow-up of the reaction was used instead of determining end point absorbance. All 
reagents used were products of Boehringer Mannheim Biochemica (Mannheim, Germany). The 
activity of NAG was indexed to urine creatinine concentration and expressed as U-NAG / crea ratio 
(units of urinary NAG activity per gram of urine creatinine). The serum cystatine C was determined 
by an immunonephelometric assay (N-Latex Cystatin C; DADE-Behring Marburg GmbH, 
Marburg/Germany) using the Behring Nephelometer BNII. Plasma renin activity was determined by 
radioimmunoassay. 
 
F 1+2 (normal, 0.4-1.1 nmol/ml), TAT (normal, 1.0-4.1 ng/ml), tPA (normal, 1-20 ng/ml) and PAI-
1 (normal, 4-43 ng/ml) were analysed with an enzyme-linked immunoabsorbent assay (ELISA) 
(Enzygnost TAT and Enzygnost F 1+2; Behring, Marburg, Germany, TintElize PAI-1 and TintElize 
tPA; Biopool International, California, USA, respectively). The inter- and intra-assay precision has 
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been previously reported (Peltonen et al. 1995). The levels of IL-6 (normal < 20 pg/ml), IL-10 
(normal < 5 pg/ml) and IL-1β (normal < 5 pg/ml) were determined using CLB (Amsterdam, The 
Netherlands) Pelikine-compact ELISA-kits and ICAM-1 (normal mean 211 ng/ml) and P-selectin 
(normal mean 82 ng/ml) using R&D Systems, Inc (Minneapolis, USA) ELISA-kits according to the 
manufacturers instructions. 
 
CT SCANNING (IV) 
 
The preoperative volume of the intraluminal thrombus was calculated using computed tomography 
images (Figure 3).  To evaluate the accuracy of the intramural thrombus volume measurements, the 
volume of the thrombus removed from the aneurysm sac during open surgery of four patients was 
measured by sinking it to saline.  
 
 
 
Figure 3. Area of the intraluminal thrombus mass (arrow) measured from one cross-sectional CT 
image. The volume of the intraluminal thrombus was calculated by measuring the area of thrombus 
from each individual cross-sectional CT image and multiplying the sum area with the number and 
thickness (1.6 – 3 mm) of the slices. Ar = the area (mm2) of the thrombus. Av = the average density 
of the CT-picture. SD = standard deviation of the density. 
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STATISTICAL ANALYSES 
 
Chi-Square-test was used for comparison of non-parametric data. The groups were compared with 
Mann-Whitney U-test and Wilcoxon paired test. Life tables were made using Kaplan-Meier and 
Log rank -method with a SPSS for Windows (Version 9.0; SPSS Inc., Chicago, Ill.) (I, II). 
 
The changes over time were compared using two-way analysis of variance (ANOVA) for repeated 
measurements with Huynh-Feldt correlation followed by Fisher´s LSD multiple-comparison test. 
The calculations were performed using the SPSS for Windows (version 9.0 (II) and 12.0.1 (IV); 
SPSS Inc., Chicago, Ill.) and NCSS (version 2000) (II, IV). 
 
The normality of distributions were established with the Kolmogoroff-Smirnoff goodness of fit test 
(IV). Correlations were calculated with parametric Pearson´s test or nonparametric Spearman´s test 
according to the normality of the distributions involved using SPSS for Windows version 12.0.1 
(IV). 
 
A p-value of < 0.05 was considered statistically significant. 
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RESULTS 
 
THE FINNISH FIRST FOUR YEAR´S EXPERIENCE OF EVAR 
 
In this series 213 abdominal aortic aneurysms were treated endovascularly, this represents 14 % of 
all and 22 % of  all electively repaired AAAs in Finland. At the same time period 16 anastomotic 
pseudoaneurysms, aortic dissections or aneurysms of the thoracic aorta were treated endovascularly. 
 
The characteristics of the patients resembled closely those in the EUROSTAR database. The 
operative risk profile of the patients according to the American Society of Anesthesiologists (ASA) 
classification was higher in the Finnish material. The procedure was performed successfully in 222 
(97 %)  patients. The deployment of the endoluminal device was unsuccessful in seven cases (3%).  
 
There were 2 deaths in the first postoperative month. The overall 30-day death rate was 0.9 %. If 
the EUROSTAR data with 2464 procedures and 3.2 % mortality rate is taken as a control, the 
present study showed a significantly lower mortality  (p= 0.04).  
 
Graft limb thrombosis was encountered during the follow-up in 20 patients (9 %). Late thrombosis 
occurred on average after 7 months postoperatively, the latest being 29 months after primary 
intervention. The occurrence of stentgraft thrombosis was almost three-fold in the Finnish series 
when compared to the EUROSTAR data with a 3.3 % thrombosis rate (p< 0,001). 
 
Primary type 2 endoleak was identified on the completion angiogram in 53 patients (23 %). 30 
sealed before the first 30-day control leaving 23 persisting endoleaks (10 %). Secondary endoleaks 
were found in 17 patients (7 %). Freedom from endoleaks and persistent endoleaks were similar to 
those in the EUROSTAR database (Figures 4, 5). Elective secondary interventions due to an 
endoleak, graft limb thrombosis or kinking were necessary in 58 patients (25 %) during the follow-
up. Three patients (1.3%) had late rupture of the abdominal aortic aneurysm. 
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     Eurostar 7/2000 n=2955                                   Finland 11/2000 n=210 
 
Figure 4. Freedom from endoleaks (Kaplan-Meier-method). 
 
 
     Eurostar 7/2000 n=2955                                   Finland 11/2000 n=210 
 
Figure 5. Freedom from persistent endoleak (Kaplan-Meier-method). 
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THE COMPARISON OF EVAR AND OPEN REPAIR OF AAA ON RENAL PROXIMAL 
TUBULAR FUNCTION 
 
Urine NAG / crea increased significantly in both groups at the time of operative wound closure as 
compared to the preoperative level (p< 0.05) indicating proximal tubular injury. There was no 
statistically significant difference between groups at any measurement point (Figure 6). Serum 
creatinine concentration, urine creatinine clearance and cumulative 24-hour urinary output were 
comparable between the groups. Plasma renin activity did not increase and there was no statistically 
significant difference between the groups. No patient developed clinical renal dysfunction. On the 
contrary, the median serum creatinine concentration decreased and the creatinine clearance 
increased after AAA repair in the both groups (Figure 7). Serum cystatin C concentration decreased 
significantly 24 hours postoperatively in the both groups when compared to the preoperative values, 
though remained within the normal reference values provided by our hospital laboratory. 
 
 
 
 
Figure 6. Urine NAG/creatinine ratio (U/g). Mean ± SEM. Pre = pre anesthesia; End = at the 
closure of the wound; 8 h = 8 h postoperatively; 24 h = 24 h postoperatively. *  p< 0.05 within 
groups compared to all other measurement points. Between groups N.S. 
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Figure 7. Median serum creatinine (µmol/l) and urine creatinine clearance (ml/s/1.73 m2) 
preopreatively (pre), 24 hours (24 h) and 48 hours (48 h) postoperatively. 
 
THE OUTCOME OF SECONDARY PROCEDURES AND CONVERSIONS 
 
A secondary intervention was performed for 40 of 110 patients (36 % of EVAR patients). In 
addition to the conversions, altogether 43 secondary procedures were performed. A conversion to 
open surgery was considered necessary in 23 patients (21 %). The thirty-day mortality in elective 
conversions (n=20) was zero. Three urgent conversions (3 % overall) were performed. Two of these 
urgent patients died, corresponding to an overall mortality of 9 % (2/23) in all conversions. The 
mortality among patients with secondary procedures other than conversions was 9 % (2/22).  
 
Most of the graft-related problems leading to conversion were among patients with first-generation 
devices (Table 7).  
 
The recovery period was uneventful in eight (57%) of the 14 secondary elective conversion 
patients. Among the other six patients, two had an acute myocardial infarction, one of them also 
suffered from worsening of pre-existing renal insufficiency. One reoperation was needed due to 
postoperative bleeding, and one because of wound dehiscence. 
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Table 7. The number of conversion procedures in first- and second-generation devices. 
 
Device Number of 
patients treated 
Median follow-up, 
months 
Conversions (%) 
First-generation: 
Vanguard, Stenford 
 
50 46.6 16 (32 %) 
Second-generation: 
Talent, Zenith, AneuRx, Excluder 
60 21.5 8 (13 %) 
 
 
 
 
EFFECTS OF INTRA-ANEURYSMAL THROMBUS ON THE INTERPLAY BETWEEN 
COAGULATION AND INFLAMMATION IN OPEN AND ENDOVASCULAR 
ABDOMINAL AORTIC ANEURYSM REPAIR 
 
Preoperative assessments 
 
The preoperative values of F 1+2 (mean, 1.5 nmol/ml), TAT (mean, 7.1 ng/ml) and D-Dimer 
(mean, 1.6 mg/l) were clearly increased, but did not differ between the groups. The inflammatory 
markers were within the normal values.  
Preoperatively the volume of the intramural thrombus correlated with CRP (β= 0.62, p=0.001) , 
PAI-1 ag (β= 0.51, p= 0.007) and IL-6 (β=0.60, p=0.001).  
 
Influence of surgery 
P-Fibrinogen increased in both groups at the third postoperative day (p< 0.05) without a difference 
between the groups. At 3 months the values returned to the preoperative level. TAT (Figure 8) 
increased further three-fold already at 24 hours and remained high three days postoperatively in the 
ENDO group, while the increase was smaller and delayed to the third day in the OPEN group (p< 
0.05). The values remained above normal at three months. D-dimer (Figure 8) increased in both 
groups after surgery (p< 0.05), and stayed above normal values at three months. Altogether at three 
 49 
  
months the mean values of D-dimer (p< 0.05), TAT (n.s.), F 1+2 (n.s.) and IL-6 (n.s.) were higher 
than preoperatively in the ENDO group, but correspondingly lower in the OPEN group. 
 
Figure 8. TAT values (normal 1-4.1 ng/ml ) in open (OPEN) and endovascular repair (ENDO) 
preoperatively, at day 1, 3 and 7 and at three months. ∗ p< 0.05 within ENDO group, and B  p< 0.05 
between the groups. Corresponding D-dimer values (normal < 0.5 mg/l). ∗ p< 0.05 within the 
groups. 
 
IL-6 (Figure 9) increased 30-fold similarly in both groups, peaking at the first postoperative day (p< 
0.05). There was a decrease in P-selectin in both groups, but in the ENDO group the decrease 
manifested later (p< 0.05). After intervention the levels of CRP (Figure 9) and S-PIIINP increased 
in both groups (p< 0.05). The increase was larger in the OPEN group, where also the blood loss was 
larger (p< 0.05). The maximal CRP response (day three CRP – preoperative CRP) correlated with 
the preoperative thrombus volume in the ENDO group (β = 0.56, p< 0.05, Spearman´s correlation). 
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Figure 9. IL-6 values (normal < 20 pg/ml) in open (OPEN) and endovascular repair (ENDO) 
preoperatively, at day 1, 3 and 7 and at three months. ∗ p< 0.05 within groups. CRP values during 
first week postoperatively (normal < 10 mg/l). ∗ p < 0.05 within groups compared to previous 
measurement and between groups. 
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DISCUSSION 
 
Limitations of the study 
 
In studies I and III the number of patients is small, and the studies reflect merely the results of early 
national and single center experience. There may also be an influence of the learning curve of the 
surgeons and interventional radiologists involved, as the first patients treated with endovascular 
devices are included. Moreover, improvements in the design of endovascular devices are 
continuously being developed, and the results of these studies may present more or less those of the 
first-generation devices, which are not currently being used anymore. Study I also included patients 
with an aneurysm of the thoracic aorta, anastomotic pseudoaneurysms and aortic dissections treated 
with an endovascular device. 
 
Studies II and IV are prospective controlled studies, but the patients were not randomised. This 
naturally may cause selection bias, especially when the patients are chosen to the groups according 
to the anatomic features of the aneurysm. In study IV a potential bias in comparison between open 
and endovascular repair may be caused by the initial differences between the groups, larger 
aneurysm and thrombus volume in the open repair group as well as procedure-induced trauma and 
blood loss. As the timing of the cytokine measurements is crucial, some effects may have been 
missed in this study. 
 
General aspects 
 
EVAR was initially developed to provide a less invasive treatment alternative to convential open 
repair of an abdominal aortic aneurysm. Later it has also been used in growing numbers to treat 
AAA patients fit for an open repair. This new method was expected to lower the mortality and 
morbidity associated with aneurysm repair by reducing the stress reaction of the patient. Short-time 
results have been promising, but the mid-term- and long-term results have been more or less 
disappointing due to the high number of complications noted leading to secondary interventions or 
even aneurysm rupture and death. This study was performed in order to elucidate whether EVAR 
has fulfilled the expectations related to this new technique. 
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 In study I the mid-term results of EVAR in Finland were assessed. The results were in accordance 
to the large EUROSTAR follow-up study, with a low 30-day mortality (0.9 %) after EVAR. The 
short-term mortality rate was significantly lower in comparison to that of elective open abdominal 
aortic aneurysm repair in Finland (Kantonen et al. 1997). Late rupture, the most fearsome 
complication after EVAR, was noted in 1.3 % of the Finnish patients. Secondary intervention was 
necessary for up to 26 % of the EVAR patients in Finland in order to avoid aneurysm ruptures after 
complications encountered during the mean follow-up of 14 months. On the other hand, in the 
EVAR 1 trial with a median follow-up of 2.9 years 15 % of the EVAR patients needed a secondary 
intervention. The lower number of secondary interventions is to be expected as the need for 
secondary interventions should decrease with the newer, more sophisticated and more durable 
endovascular devices (Torella 2004). Still, EVAR leads to a high number of adverse events and 
reinterventions, which are rare after open repair (EVAR trial participants 2005a). In study III 
presenting mid-term results after EVAR in Helsinki University Central Hospital, secondary 
intervention was performed for 36 % of the patients. 
 
When endovascular re-interventions fail to treat the complications noted after EVAR, conversion to 
open repair has to be considered. Conversion has been regarded as failure of endovascular 
treatment, and due to high mortality rates reported, avoided in many centers. In some reports a few 
patients have even been left under mere observation when EVAR has failed. In study III the results 
of a rather liberal conversion policy were clarified. Conversion was performed for 21 % of the 
EVAR patients which is among the highest numbers reported. Yet, conversion surgery was found to 
be safe with a zero mortality when performed electively. As the repetitious maintenance procedures 
of secondary interventions may endanger the patients outcome, conversion may be regarded as a 
noteworthy alternative. 
 
In our material conversion mortality was lower than in earlier reports. We believe that one of the 
most important factors was careful preoperative evaluation and preparation of the patient to 
conversion. According to our results, conversion can be performed safely. However, in high-risk 
patients, an analysis of the risks of conservative treatment compared to those of conversion has to 
be made carefully and individually to each patient. 
 
Renal dysfunction is a well-known complication after open AAA repair. In an earlier report the risk 
for deterioration of renal function was less in EVAR compared to open repair (Wijnen et al. 2001). 
Another study comparing open and endovascular repair suggested a greater renal injury in 
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endovascular repair (Boyle et al. 2000). In our study II, there was no difference between the groups 
and EVAR did not protect kidneys from renal proximal tubular dysfunction associated with open 
repair. A comparable, reversible increase in U-NAG/crea was seen in both study groups indicating 
similar renal dysfunction, which did not lead to permanent changes in renal function. On the 
contrary less sensitive markers serum creatinine and urine creatinine clearance indicated that renal 
function actually improved in both groups after surgery. This was presumably due to our 
anaesthesiologists´ active hydration policy. 
 
In order to evaluate the impact of the aneurysmal thrombus and to compare the consequences of the 
stress reaction of the patient in EVAR and open repair, the reactions in inflammation and 
coagulation were investigated in study IV. An upregulated state of thrombin formation and fibrin 
turnover was found in AAA patients. The active state of blood coagulation and fibrinolysis in these 
patients further increased after surgery and persisted at three months.  
 
A significant correlation between the preoperative volume of the intraluminal thrombus and the 
circulating IL-6 levels was demonstrated, indicating that the thrombotic content of the aneurysm sac 
is the likely source of the increased circulating IL-6 levels. Even though intramural thrombus in 
AAA has previously been reported to contain high levels of IL-6 (Swartbol et al. 1998), a 
correlation between the thrombus volume and the levels of the circulating IL-6 has not previously 
been reported. Earlier reports have used inaccurate methods measuring the volume of the thrombus 
but we calculated the corresponding volume using accurate computed tomography and measured 
the area of thrombus from each individual cross-sectional CT image.  
 
A significant rise of IL-6, which did not differ between the study groups was detected following 
AAA repair. As the inflammatory response is complex (Levi 2003, Swartbol et al. 2001), the extent 
of surgical trauma or ischaemia-reperfusion does not explain these results. The sustained and 
enhanced production of IL-6 of the intra-aneurysmal thrombotic mass in the EVAR group may 
contribute to the ongoing inflammation and the interplay between inflammation and coagulation 
and fibrinolysis activity.  
 
The production and release of CRP is induced by IL-6 (Ertel et al. 1990, Schluter et al. 1991, Soong 
et al. 1994). In this study, along with IL-6, the CRP levels were also significantly associated with 
the volume of the intraluminal thrombus. The maximal postoperative CRP response and the 
thrombus volume were found to be associated only in the ENDO group where the thrombus mass 
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remained and even new thrombus formation possibly occur inside the aneurysm sac, which is 
isolated from the circulation by the endovascular device.  
 
The preoperative association of intraluminal thrombus with IL-6 and CRP suggest that there is a 
constant inflammatory and prothrombotic activity in the aneurysmal thrombus, which remains after 
the endovascular repair. This may explain the similarities in the postoperative activities in the 
inflammatory and thrombotic systems in the open and the endovascular repair, despite the 
differences in the extent of the surgical trauma and the ischaemia-reperfusion injury.  
 
It is also of significance that only in the EVAR group the inflammatory and prothrombotic activities 
in the intra-aneurysmal thrombus seem to continue after three months after the initial response to 
the procedure. This may provoke late thrombotic complications, like graft limb thromboses in the 
EVAR patients. Interestingly in the EVAR 1 study where the aneurysm-related mortality was lower 
in the EVAR-group, and all-cause mortality was similar between the groups, myocardial infarction, 
stroke and other cardiovascular events were more frequently the late cause of death among EVAR 
patients than among open repair patients (EVAR trial participants 2005a). 
 
EVAR was initially developed to provide a less invasive treatment method for patients with several 
co-morbidities. The short-term results have been promising: EVAR has fulfilled expectation related 
to it in the form of lower mortality, lower blood loss, and faster recovery of patients. In several 
studies on high-risk patients, EVAR has reached substantially lower operative mortality compared 
to open repair (Geraghty and Sicard 2003), however, the mid-term results are not as convincing. 
The EVAR 2 trial surprisingly proposed that EVAR does not lower the all-cause mortality among 
these patients when compared to conservative treatment. In many centers EVAR has not been 
offered for patients with low operative risk and long life-expectancy (Cronenwett 2005), but the 
mid-term results of EVAR 1 trial still show a 3 % reduction in aneurysm-related mortality even 
though there was no difference between the study groups in all-cause mortality. 
 
Despite the relative draw-backs noted in EVAR, the number of endovascular procedures is 
constantly increasing, especially where the economic forces tend to direct the course of attitudes. 
There are, in other words, conflicting pressures from consumers keen to adopt new and minimally 
invasive techniques, despite the view that EVAR should still be considered an experimental 
procedure (Michaels 2005). 
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The late complications noted, especially aneurysm ruptures following EVAR, and the lack of long-
term results in randomised studies comparing EVAR and open repair still question the true benefits 
of EVAR, or, as Longo and Eskandari (2004) noted “Ultimately, long term studies looking at 
mortality and issues of surveillance and reintervention will determine if those placing endografts are 
prescient visionaries or fools caught up in a new technology”. 
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CONCLUSIONS 
 
The 30-day mortality after EVAR in Finland is low (0.9%). The mid-term treatment results with 
mostly first-generation endografts are more disappointing because of the detected endoleaks, the 
risk of late rupture, stent graft kinking and numerous graft limb thromboses and the need for 
secondary interventions. 
 
A temporary renal tubular dysfunction is found both in open and in endovascular AAA repair which 
do not lead to permanent changes in renal function. Endovascular AAA repair does not protect renal 
proximal tubular function. 
 
As a conversion seems to be less hazardous when performed electively, it could be an alternative 
treatment method in complex, failing first-generation stent-grafts as it may reduce mortality 
associated with urgent conversions. 
 
Preoperatively both the prothrombotic and the fibrinolytic mechanisms are activated in patients with 
AAA. The activation seems to persist in EVAR patients three months postoperatively. The 
intraluminal thrombus may induce prothrombotic and inflammatory interactions, which may 
counteract the potential benefits gained with endovascular aortic aneurysm repair. 
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